NB.1.8.1: Omicron Subvariant’s Rise in US COVID-19 Cases

CDC data indicates that the Omicron subvariant NB.1.8.1 now accounts for approximately 37% of US COVID-19 cases, rivaling the current dominant strain LP.8.1 (38%).

While NB.1.8.1’s global prevalence is around 25%, its rapid increase since its initial detection in late January raises concerns about a potential summer surge. However, current US hospitalization and death rates remain low, and the test positivity rate is only slightly elevated.

Although NB.1.8.1 doesn’t appear to cause more severe illness than other circulating variants, mutations suggest potentially increased transmissibility. This, coupled with waning population immunity following a mild winter, could contribute to a larger peak this summer.

Experts like Edoardo Colzani of the ECDC emphasize that NB.1.8.1 isn’t expected to significantly impact vaccine effectiveness against severe disease. However, the possibility of increased transmission warrants monitoring.

The overall risk remains low due to widespread vaccination and existing population immunity, but the situation underscores the ongoing need for vigilance and preparedness.

阅读中文版 (Read Chinese Version)

Disclaimer: This content is aggregated from public sources online. Please verify information independently. If you believe your rights have been infringed, contact us for removal.